Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruzinurad DDI with Febuxostat and Colchicine in Gout
NCT03131583Phase 1Completed
- Sponsor
- Hengrui
- Start
- Feb 2017
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ruzinurad in gout, sponsored by Hengrui. Primary endpoints: Maximum Observed Concentration at Day 8, Area Under the Concentration-Time Curve at Day 8 and 1 more. Started Feb 2017; status: completed.
02
Drugs
ruzinurad
03
Conditions
gout
Beyond the preview
Go deeper on NCT03131583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03131583.